Macugen

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2001-2016
0102020012016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
BACKGROUND To report the morphologic and functional outcomes resulting from the use of intravitreal pegaptanib (IVP) sodium… (More)
Is this relevant?
2009
2009
PURPOSE To report the functional and anatomical outcomes resulting from the use of intravitreal pegaptanib sodium (Macugen) in… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
2009
2009
PURPOSE To describe a patient with nonexudative age-related macular degeneration (AMD) who underwent intravitreal pegaptanib… (More)
Is this relevant?
2008
2008
The 2'-fluoro/2'-O-methyl modified RNA aptamer Macugen is a potent inhibitor of the angiogenic regulatory protein, VEGF165… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
Is this relevant?
2008
2008
PURPOSE To report results of treatment of vascularly active familial exudative vitreoretinopathy (FEVR) with pegaptanib sodium… (More)
Is this relevant?
2007
2007
To compare the antiproliferative and cytotoxic properties of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab… (More)
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2007
2007
The purpose of this paper was to describe a patient with pericentral retinitis pigmentosa (RP) and cystoid macular edema (CME… (More)
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2006
Highly Cited
2006
OBJECTIVE To study effects of intravitreal pegaptanib (Macugen) on retinal neovascularization. DESIGN Retrospective analysis of… (More)
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Aptamers recognize their targets with extraordinary affinity and specificity. The aptamer-based therapeutic, Macugen, is derived… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?